Department of Communication and Cognition, Tilburg School of Humanities and Digital Sciences, Tilburg University, Tilburg, The Netherlands; Department of Research and Development, Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands.
Department of Urology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Patient Educ Couns. 2022 Aug;105(8):2731-2739. doi: 10.1016/j.pec.2022.04.017. Epub 2022 May 4.
We investigated how healthcare professionals (HPs) communicate personalized risks of treatment side-effects to patients with localized prostate cancer during consultations, and explored how these patients perceive and use such risks during treatment decision-making.
Patient consultations with nurse practitioners and urologists discussing personalized risks of urinary incontinence after prostatectomy were audiotaped, transcribed, and coded. Patients (n = 27) were then interviewed to explore their perceptions and use of personalized side-effect risks.
HPs explained personalized risks by discussing risk factors, which was appreciated and recalled by patients. Personalized risks were typically communicated both numerically and verbally (70%). When using numbers, HPs always used percentages, but rarely used natural frequencies (14%). Uncertainty was disclosed in only 34% of consultations. One-third of patients used personalized risks in their treatment decision-making by either switching to another treatment or sticking to their initial preference.
Patients value and use personalized side-effect risks during treatment decision-making. Clearly explaining the relationship between risk factors and personalized risk estimates may help patients understand and recall those. Practice implications HPs should not only give patients specific and precise numerical risk information, but should also put effort in explaining how the personalized side-effect risks are determined.
本研究旨在调查医疗保健专业人员(HPs)在与局限性前列腺癌患者的咨询中如何向患者传达治疗副作用的个体化风险,并探讨这些患者在治疗决策过程中如何感知和使用这些风险。
对护士从业者和泌尿科医生讨论前列腺切除术尿失禁个体化风险的患者咨询进行录音、转录和编码。然后对患者(n=27)进行访谈,以探讨他们对个体化副作用风险的感知和使用情况。
HPs 通过讨论风险因素来解释个体化风险,这得到了患者的赞赏和回忆。个体化风险通常以数字和口头形式(70%)传达。当使用数字时,HPs 总是使用百分比,但很少使用自然频率(14%)。仅在 34%的咨询中披露了不确定性。三分之一的患者在治疗决策中使用个体化风险,要么选择另一种治疗方法,要么坚持最初的偏好。
患者在治疗决策中重视并使用个体化副作用风险。清楚地解释风险因素与个体化风险估计之间的关系可以帮助患者理解和回忆这些风险。实践意义 HPs 不仅应向患者提供具体和准确的数值风险信息,还应努力解释个体化副作用风险是如何确定的。